Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the efficacy and safety of programmed death-1 blockad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ansell, Stephen M., Minnema, Monique C., Johnson, Peter, Timmerman, John M., Armand, Philippe, Shipp, Margaret A., Rodig, Scott J., Ligon, Azra H., Roemer, Margaretha G.M., Reddy, Nishitha, Cohen, Jonathon B., Assouline, Sarit, Poon, Michelle, Sharma, Manish, Kato, Kazunobu, Samakoglu, Selda, Sumbul, Anne, Grigg, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6528729/
https://ncbi.nlm.nih.gov/pubmed/30620669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00766
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados